CLC Questionnaire

If you are interested in joining our Chemical Library Consortium and obtaining our small molecule screening collection, please fill out the form below.

To improve the size and diversity of our screening collection, the BU-CMD has recently begun intake of small molecules from external (non-BU) academic groups in the BU-CMD Repository. If you are interested in screening these compounds, before applying, Boston University strongly encourages you to review the agreements and instructions that recipient institutions must agree to in order to receive externally-deposited materials from the BU-CMD. More details can be found at https://www.bu.edu/cmd/mta/

  • The BU-CMD Repository Collection, which includes the original BU-CMD Screening Collection plus externally-sourced compounds, is available for screening free of charge with support from the NCATS CTSA CCIA program.
  • The original BU-CMD Screening Collection, containing molecules sourced only from BU, remains available, but may cost a fee to distribute. Please contact the BU-CMD for more details.

CLC Questionnaire

  • (select all that apply)
  • Our standard stock supply is 0.2 micromoles dry film, to be reconstituted in DMSO to desired by concentration by recipient. If this is not sufficient for your needs, please elaborate below.
  • Please describe the area of biology you are studying and your assay (2-3 sentences only).
  • Briefly indicate any evidence you have that your assay provides both a sensitive and specific readout for your biological question of interest (2-3 sentences only).
  • Please list one review article on the pathway or protein targeted by your screen (not necessarily authored by you) that would provide sufficient background reading to familiarize BU-CMD personnel with your assay.
  • For modifier screens only.
  • Average full collection distributions are 2000-3000 compounds, with smaller numbers available as focused sets.
  • Explain any secondary assays that will be used for further characterization of compounds which score as positives in your primary screen. Also describe how they will help prioritization of positives.
  • Please provide an estimate as to when data will become available. If your assay is still being developed, please include a realistic estimate as to when your assay will be ready for BU-CMD compounds.
  • Are you agreeable to providing follow-up information to other BU-CMD biological collaborators on the results of your screening (e.g., details of the assay, number and potency of "hits," the structure(s) of "hits" as related to the molecular or cellular target)?
  • If hits are identified in your screen, would you be interested in partnering with the BU-CMD in collaborative medicinal chemistry projects?